Hovione Technology’s 8Shot dry powder inhaler has been selected as a finalist for the 2021 Medical Design Excellence Awards (MDEA) in the Drug-Delivery and Combination Products category, the company said. The 8Shot DPI, which is designed for delivery of doses up to 400 mg, previously won a Red Dot 2020 Product Design Award in the Healthcare Daily Living Aids category. Hovione Technology is developing the device in partnership with design company WeADD.
Hovione Technology CEO Peter Villax commented, “The MDEA competition is a premier awards program for the medtech industry. The selection of our 8Shot DPI to be among the list of finalists in the Drug-Delivery and Combination products category is a great achievement for the Hovione Technology team.”
Director of Technology Development and Licensing João Ventura Fernandes added, “We are honored and delighted to be a finalist of the MDEA competition, together with our design and development partner WeADD. This nomination recognizes our medical product design efforts with the 8Shot DPI to make it as attractive and as easy to use as possible to patients, a necessary step to regular use and treatment compliance.”
WeAdd CEO Agostinho Carvalho said, “We are very happy to be nominated as MDEA finalist together with Hovione Technology. This is a result of a fruitful long-term collaboration between our two companies in the design and development of medical device products. The 8Shot DPI offers a unique, patient friendly inhaler design and makes available a patented high payload DPI to pharmaceutical companies, off-the-shelf, ready to support their developments.”
Read the Hovione Technology press release.
